JP2024537397A5 - - Google Patents
Info
- Publication number
- JP2024537397A5 JP2024537397A5 JP2024522500A JP2024522500A JP2024537397A5 JP 2024537397 A5 JP2024537397 A5 JP 2024537397A5 JP 2024522500 A JP2024522500 A JP 2024522500A JP 2024522500 A JP2024522500 A JP 2024522500A JP 2024537397 A5 JP2024537397 A5 JP 2024537397A5
- Authority
- JP
- Japan
- Prior art keywords
- self
- fusion polypeptide
- polypeptide
- mutation
- assembling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256566P | 2021-10-16 | 2021-10-16 | |
| US63/256,566 | 2021-10-16 | ||
| PCT/CA2022/051516 WO2023060358A1 (en) | 2021-10-16 | 2022-10-14 | Modified multabody constructs, compositions, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537397A JP2024537397A (ja) | 2024-10-10 |
| JP2024537397A5 true JP2024537397A5 (enExample) | 2025-10-22 |
Family
ID=85987098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522500A Pending JP2024537397A (ja) | 2021-10-16 | 2022-10-14 | 改変されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250002564A1 (enExample) |
| EP (1) | EP4416188A4 (enExample) |
| JP (1) | JP2024537397A (enExample) |
| KR (1) | KR20240101591A9 (enExample) |
| CN (1) | CN118488972A (enExample) |
| CA (1) | CA3235526A1 (enExample) |
| WO (1) | WO2023060358A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
| CN121449754A (zh) * | 2019-08-01 | 2026-02-03 | 病童医院 | 多价和多特异性纳米颗粒平台和方法 |
| AU2022212978A1 (en) * | 2021-01-28 | 2023-08-31 | The Hospital For Sick Children | Multabody constructs, compositions, and methods |
-
2022
- 2022-10-14 KR KR1020247016004A patent/KR20240101591A9/ko active Pending
- 2022-10-14 CN CN202280077822.2A patent/CN118488972A/zh active Pending
- 2022-10-14 WO PCT/CA2022/051516 patent/WO2023060358A1/en not_active Ceased
- 2022-10-14 CA CA3235526A patent/CA3235526A1/en active Pending
- 2022-10-14 EP EP22879728.8A patent/EP4416188A4/en active Pending
- 2022-10-14 JP JP2024522500A patent/JP2024537397A/ja active Pending
- 2022-10-14 US US18/701,020 patent/US20250002564A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641967B2 (ja) | ヒト化ｃｌｄｎ１８．２抗体 | |
| US20250171545A1 (en) | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES | |
| CN117143247A (zh) | 双特异性蛋白质及其制备方法 | |
| AU2014332458A1 (en) | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies | |
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2023547662A (ja) | Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物 | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| CN118660907A (zh) | 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| JP2024533485A5 (enExample) | ||
| US20260055171A1 (en) | Vegf antagonists and methods of use thereof | |
| JP2024533487A5 (enExample) | ||
| RU2861719C2 (ru) | Антитела к pd-1 и слитые белки | |
| US20250304687A1 (en) | Multispecific antibodies targeting cd79b/cd3 and the uses thereof | |
| KR20250157402A (ko) | 다가 항스파이크 단백질 결합 분자 및 그 용도 | |
| RU2024110045A (ru) | Нацеленные на dr5 multabody для лечения злокачественного новообразования | |
| JP2024537398A5 (enExample) | ||
| HK40131631A (zh) | 多价抗刺突蛋白结合分子及其用途 | |
| KR20250156759A (ko) | 다가 항스파이크 단백질 결합 분자 및 이의 용도 | |
| CN121873202A (zh) | Il-2突变体、pd1抗体×il-2突变体融合蛋白及其应用 | |
| JP2025528101A (ja) | 多重特異性ポリペプチド複合体 | |
| WO2023288078A1 (en) | Coronavirus antibodies and uses thereof | |
| CN118488971A (zh) | 优化的Multabody构建体、组合物和方法 | |
| HK40076734A (en) | Composition of triax antibodies and method of making and using thereof |